Biocytogen Pharmaceuticals (Beijing) Co (FRA:I54) Net Interest Margin (Bank Only) %

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:I54 Biocytogen Pharmaceuticals (Beijing) Co Ltd FRA:I54
79 GF Score
Price €5.55
GF Value €3.32
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Biocytogen Pharmaceuticals (Beijing) Co Net Interest Margin (Bank Only) %?

Net Interest Margin (Bank Only) % only applies to banks.

FRA:I54
79GF Score
Biocytogen Pharmaceuticals (Beijing) Co Ltd FRA:I54
Net Interest Margin (Bank Only) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Biocytogen Pharmaceuticals (Beijing) Co (FRA:I54) Overvalued in 2026?

Based on GuruFocus' analysis, Biocytogen Pharmaceuticals (Beijing) Co stock appears to be overvalued. The current stock price of €5.55 is trading 67.2% above its estimated GF Value™ of €3.32. GuruFocus considers Biocytogen Pharmaceuticals (Beijing) Co to be Significantly Overvalued.

Key valuation signals for FRA:I54:

  • Net Interest Margin (Bank Only) %:
  • GF Value™: €3.32 vs. price of €5.55 (67.2% above fair value)
  • GF Score™: 79/100 with 2 warning signs

No single metric tells the full story. See the FRA:I54 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Biocytogen Pharmaceuticals (Beijing) Co Business Description

Other Exchanges 02315:Hong Kong688796:China
Address 12 Baoshen South Street, Daxing Bio-Medicine Industry Park, Daxing District, Beijing, CHN
Biocytogen Pharmaceuticals (Beijing) Co Ltd is a biopharmaceutical and pre-clinical research services company. It has two Core Products, YH003 and YH001. YH003 is a recombinant humanized agonistic anti-Cluster of Differentiation 40 (CD40) Immunoglobulin G2 (IgG2) monoclonal antibody and YH001 is a recombinant humanized anti-CTLA-4, a protein receptor expressed constitutively on T cells that functions as an immune checkpoint and downregulates immune responses, Immunoglobulin G1 (IgG1) monoclonal antibody. YH003 is being developed for pancreatic ductal adenocarcinoma, melanoma, and other developed solid tumors. YH001 is being developed for hepatocellular carcinoma (HCC), non-small-cell lung carcinoma (NSCLC), and other solid tumors.
79GF Score

Get the complete analysis for FRA:I54

Net Interest Margin (Bank Only) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.55
Price
€3.32
GF Value